Mitoxantrone diacetate
Based on 48 publication(s) in Google Scholar
Mitoxantrone diacetate is a potent topoisomerase II inhibitor. Mitoxantrone diacetate also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 μM. Mitoxantrone diacetate induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone diacetate shows antitumor activity. Mitoxantrone diacetate also has anti-orthopoxvirus activity with EC50s of 0.25 μM and and 0.8 μM for cowpox and monkeypox, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 70711-41-0
- Formel: C26H36N4O10
- Molecular Weight:564.58
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Mitoxantrone diacetate
More- Signal Transduct Target Ther. 2026 Jun 4;11(1):215. [Abstract]
- Adv Mater. 2024 Jul;36(27):e2313097. [Abstract]
- Light Sci Appl. 2024 Oct 31;13(1):304. [Abstract]
- Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]
- Nat Commun. 2020 Apr 14;11(1):1792. [Abstract]
- Exp Mol Med. 2025 Nov;57(11):2559-2573. [Abstract]
- J Am Chem Soc. 2022 Jun 15;144(23):10407-10416. [Abstract]
- Mol Cell. 2024 Jul 11;84(13):2553-2572.e19. [Abstract]
- J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Cell Rep Med. 2024 Feb 20;5(2):101388. [Abstract]
- J Control Release. 2024 Nov 12:376:1271-1287. [Abstract]
- Cell Death Dis. 2025 Dec 19;16(1):894. [Abstract]
- Pharmacol Res. 2024 Jun:204:107208. [Abstract]
- Int J Biol Sci. 2022 Mar 21;18(6):2568-2582. [Abstract]
- Acta Pharmacol Sin. 2025 Jan;46(1):159-170. [Abstract]
- Acta Pharmacol Sin. 2023 Mar;44(3):584-595. [Abstract]
- Int J Biol Macromol. 2025 Mar:296:139582. [Abstract]
- Drug Deliv. 2022 Dec;29(1):2561-2578. [Abstract]
- EMBO Mol Med. 2024 Nov;16(11):2856-2881. [Abstract]
- Talanta. 2024 Jul 1:274:125987. [Abstract]
- Biochem Pharmacol. 2026 Mar 15:249:117903. [Abstract]
- RSC Adv. 2025 Aug 15;15(35):28965-28983. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Int J Mol Sci. 2026 Mar 11;27(6):2587. [Abstract]
- Int J Mol Sci. 2025 Apr 17;26(8):3790. [Abstract]
- Cell Oncol (Dordr). 2020 Dec;43(6):1099-1116. [Abstract]
- J Enzyme Inhib Med Chem. 2025 Dec;40(1):2518191. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- PLoS Pathog. 2026 Jan 26;22(1):e1013903. [Abstract]
- Cancers (Basel). 2020 Aug 4;12(8):2169. [Abstract]
- Med Oncol. 2020 Nov 19;37(12):116. [Abstract]
- RSC Med Chem. 2025 Apr 30;16(7):3197-3212. [Abstract]
- BMC Cancer. 2025 Jan 7;25(1):24. [Abstract]
- BMC Cancer. 2021 Oct 13;21(1):1101. [Abstract]
- J Pharm Pharmacol. 2022 Jan 5;74(1):41-56. [Abstract]
- Drug Metab Dispos. 2025 Mar;53(3):100046. [Abstract]
- ChemMedChem. 2025 Oct 6;20(19):e202500429. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- Pharm Dev Technol. 2021 Jul;26(6):673-681. [Abstract]
- Hematology. 2026 Dec 31;31(1):2664314. [Abstract]
- EJHaem. 2025 Aug 30;6(5):e70140. [Abstract]
- University of Bonn. 2025 Feb.
- Patent. US20240307414A1.
- University of California, Irvine. 2024.
- bioRxiv. 2024 September 07.
- bioRxiv. 2023 Jan 13.
- Research Square Print. November 28th, 2022.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Apoptosis Analysis
-
IF
-
WB
Alle Topoisomerase Isoform-spezifische Produkte anzeigen
MoreAlle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Topoisomerase II |
PKC 8.5 μM (IC50) |
Mitoxantrone diacetate inhibits PKC in a competitive manner with respect to histone H1, and its Ki value is 6.3 μM and in a non-competitive manner with respect to phosphatidylserine and ATP[1].
Mitoxantrone diacetate (0.5 μg/mL, 48 h) induces a decrease in B-CLL cells. Mitoxantrone diacetate induces DNA fragmentation and the proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), demonstrating that the cytotoxic effect of Mitoxantrone diacetate is due to induction of apoptosis[2].
Mitoxantrone diacetate shows cytotoxicity to human breast carcinoma cell lines MDA-MB-231 and MCF-7 with IC50 values of 18 and 196 nM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mitoxantrone diacetate (IV, 0-3.2 mg/kg/day) shows effective antitumor activities and produces a 60% ILS (increase in lifespan) at 3.2 mg/kg in SC implanted Lewis lung carcinoma[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 70711-41-0
-
Molecular Weight 564.58
-
Formel C26H36N4O10
-
SMILES
O=C1C2=C(C(NCCNCCO)=CC=C2NCCNCCO)C(C3=C(O)C=CC(O)=C13)=O.O=C(C)O.O=C(C)O
-
Synonyms
Mitozantrone diacetate; NSC 301739 diacetate
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (48)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer. [Abstract]2026 Jun 4;11(1):215. PMID: 42236688 -
Adv Mater
Dismantlable Coronated Nanoparticles for Coupling the Induction and Perception of Immunogenic Cell Death. [Abstract]2024 Jul;36(27):e2313097. PMID: 38643386 -
Light Sci Appl
Dynamic synthetic-scanning photoacoustic tracking monitors hepatic and renal clearance pathway of exogeneous probes in vivo. [Abstract]2024 Oct 31;13(1):304. PMID: 39482292 -
Nat Cell Biol
2024 Jun;26(6):917-931. PMID: 38714852
Mitoxantrone diacetate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]
HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).
Mitoxantrone diacetate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2024 Jun;26(6):917-931. [Abstract]
HeLa cells were pre-treated with DMSO or Mitoxantrone (10 μM, 1 h) followed by Tg treatment (1 μM, 3 h).
-
Nat Commun
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]2020 Apr 14;11(1):1792. PMID: 32286289 -
Exp Mol Med
PYCR1 drives lung cancer progression through functional interactions with EGFR and TLR signaling pathways. [Abstract]2025 Nov;57(11):2559-2573. PMID: 41254241
Mitoxantrone diacetate purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Nov;57(11):2559-2573. [Abstract]
The USP11 inhibitor Mitoxantrone (5-20 μM; 24 h) was treated to A549 (western blotting for EGFR) cells. The EGFR protein levels were assessed by western blotting using an anti-EGFR antibody.
-
J Am Chem Soc
Target Profiling of an Iridium(III)-Based Immunogenic Cell Death Inducer Unveils the Engagement of Unfolded Protein Response Regulator BiP. [Abstract]2022 Jun 15;144(23):10407-10416. PMID: 35658433 -
Mol Cell
2024 Jul 11;84(13):2553-2572.e19. PMID: 38917794 -
J Exp Clin Cancer Res
CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways. [Abstract]2025 Aug 5;44(1):228. PMID: 40764945
Mitoxantrone diacetate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]
U87-MG and U251 cells with stable CSRP2 overexpression (CSRP2) were treated with or without 0.5 µM Mitoxantrone (MTO) for indicated time periods and the cell proliferation was analyzed. Cells transfected with control vector (NC) were used as a negative control. Two-way ANOVA with Sidak’s post hoc test, n = 6 per group for U87-MG and U251.
Mitoxantrone diacetate purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2025 Aug 5;44(1):228. [Abstract]
U87-MG and U251 cells with stable CSRP2 overexpression were treated with 0.5 µM Mitoxantrone (MTO) for 48 h and cell apoptosis was measured by flow cytometry
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Cell Rep Med
Cholinergic signaling via muscarinic M1 receptor confers resistance to docetaxel in prostate cancer. [Abstract]2024 Feb 20;5(2):101388. PMID: 38262412 -
J Control Release
A personalized vaccine combining immunogenic cell death-induced cells and nanosized antigens for enhanced antitumor immunity. [Abstract]2024 Nov 12:376:1271-1287. PMID: 39515613 -
Cell Death Dis
USP11 promotes colorectal cancer progression by stabilizing EGFR and TRAF6: a potential therapeutic target in EGFR- and TLR-driven tumorigenesis. [Abstract]2025 Dec 19;16(1):894. PMID: 41419456 -
Pharmacol Res
2024 Jun:204:107208. PMID: 38729587 -
Int J Biol Sci
ERK-mediated Cytoplasmic Retention of USP11 Contributes to Breast Cancer Cell Proliferation by Stabilizing Cytoplasmic p21. [Abstract]2022 Mar 21;18(6):2568-2582. PMID: 35414784 -
Acta Pharmacol Sin
USP11 promotes renal tubular cell pyroptosis and fibrosis in UUO mice via inhibiting KLF4 ubiquitin degradation. [Abstract]2025 Jan;46(1):159-170. PMID: 39147900 -
Acta Pharmacol Sin
Deubiquitinating enzyme USP11 promotes renal tubular cell senescence and fibrosis via inhibiting the ubiquitin degradation of TGF-β receptor II. [Abstract]2023 Mar;44(3):584-595. PMID: 36045219 -
Int J Biol Macromol
2025 Mar:296:139582. PMID: 39798757 -
Drug Deliv
Enzyme-triggered- and tumor-targeted delivery with tunable, methacrylated poly(ethylene glycols) and hyaluronic acid hybrid nanogels. [Abstract]2022 Dec;29(1):2561-2578. PMID: 35938558 -
EMBO Mol Med
Targeting USP11 regulation by a novel lithium-organic coordination compound improves neuropathologies and cognitive functions in Alzheimer transgenic mice. [Abstract]2024 Nov;16(11):2856-2881. PMID: 39394468 -
Talanta
High-throughput BCRP inhibitors screening system based on styrene maleic acid polymer membrane protein stabilization strategy and surface plasmon resonance biosensor. [Abstract]2024 Jul 1:274:125987. PMID: 38552478 -
Biochem Pharmacol
Ticagrelor reverses multidrug resistance in breast cancer by inhibiting PI3K/AKT/mTOR pathway and suppressing ABCB1 expression and function. [Abstract]2026 Mar 15:249:117903. PMID: 41846011 -
RSC Adv
Novel self-assembled metal-phenolic nanoplatforms for triple-negative breast cancer treatment: photothermal-chemotherapy/ferroptosis synergy inducing immunogenic cell death. [Abstract]2025 Aug 15;15(35):28965-28983. PMID: 40861997 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Int J Mol Sci
2026 Mar 11;27(6):2587. PMID: 41898448 -
Int J Mol Sci
2025 Apr 17;26(8):3790. PMID: 40332396 -
Cell Oncol (Dordr)
Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression. [Abstract]2020 Dec;43(6):1099-1116. PMID: 32710433 -
J Enzyme Inhib Med Chem
Identification of chemical scaffolds for targeting ubiquitin-specific protease 11 (USP11) through high-throughput virtual screening. [Abstract]2025 Dec;40(1):2518191. PMID: 40588719 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
PLoS Pathog
Anti-orthopoxvirus drugs inhibit lumpy skin disease virus replication by targeting viral DNA polymerase. [Abstract]2026 Jan 26;22(1):e1013903. PMID: 41587213 -
Cancers (Basel)
Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. [Abstract]2020 Aug 4;12(8):2169. PMID: 32759815 -
Med Oncol
Proteasome inhibitors attenuates mitoxantrone-triggered immunogenic cell death in prostate cancer cells. [Abstract]2020 Nov 19;37(12):116. PMID: 33215275 -
RSC Med Chem
Biological assessments of novel ultrasound-synthesized 2-arylbenzimidazole derivatives: antiproliferative and antibacterial effects. [Abstract]2025 Apr 30;16(7):3197-3212. PMID: 40352670 -
BMC Cancer
Preclinical studies of the falnidamol as a highly potent and specific active ABCB1 transporter inhibitor. [Abstract]2025 Jan 7;25(1):24. PMID: 39773145 -
BMC Cancer
Bortezomib potentiates antitumor activity of mitoxantrone through dampening Wnt/β-catenin signal pathway in prostate cancer cells. [Abstract]2021 Oct 13;21(1):1101. PMID: 34645397 -
J Pharm Pharmacol
An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation. [Abstract]2022 Jan 5;74(1):41-56. PMID: 34986225 -
Drug Metab Dispos
Identification of selective substrates and inhibitors of the major human renal uptake transporters. [Abstract]2025 Mar;53(3):100046. PMID: 40024137 -
ChemMedChem
Benzoxazole-Acrylonitriles: Dual Bioactivity and DNA Binding from a Sustainable Synthetic Approach. [Abstract]2025 Oct 6;20(19):e202500429. PMID: 40983325 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
Pharm Dev Technol
A promising dual-drug targeted delivery system in cancer therapy: nanocomplexes of folate-apoferritin-conjugated cationic solid lipid nanoparticles. [Abstract]2021 Jul;26(6):673-681. PMID: 33896342 -
Hematology
XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia. [Abstract]2026 Dec 31;31(1):2664314. PMID: 42026967 -
EJHaem
2025 Aug 30;6(5):e70140. PMID: 40896243 -
-
-
-
-
-
Reinheit & Dokumentation
Verweise
[1]. Takeuchi N, et al. Inhibitory effect of mitoxantrone on activity of protein kinase C and growth of HL60 cells. J Biochem. 1992 Dec;112(6):762-7. [Content Brief]
[2]. Bellosillo B, et al. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6. [Content Brief]
[3]. Vibet S, et al. Differential subcellular distribution of mitoxantrone in relation to chemosensitization in two human breast cancer cell lines. Drug Metab Dispos. 2007 May;35(5):822-8. [Content Brief]
[4]. Fujimoto S, et al. Antitumor activity of mitoxantrone against murine experimental tumors: comparative analysis against various antitumor antibiotics. Cancer Chemother Pharmacol. 1982;8(2):157-62. [Content Brief]
[5]. Sharon E Altmann, et al. Inhibition of cowpox virus and monkeypox virus infection by mitoxantrone. Antiviral Res. 2012 Feb;93(2):305-308. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Mitoxantrone diacetate Related Classifications
HY-13502B Related Classifications
Powered by Bioz